Search results
HEALEY ALS Platform Trial. This is the first ALS platform trial, accelerating the path to new ALS therapies by testing multiple treatments at once, reducing the cost of research by 30%, decreasing the trial time by 50% and increasing patient participation by 67%. Platform Trial Details. Trial News & Webinars.
- Our Supporters
We are very thankful for our longstanding partnership with...
- What to Expect
Within the Regimen, you will be randomized again, with a 3:1...
- Study Drugs
A prior first-in-human study of ABBV-CLS-7262 showed that...
- For Patients
The HEALEY ALS Platform Trial was designed to decrease the...
- Clinical Trials
Massachusetts General Hospital invites patients and the...
- About The Trial
The HEALEY ALS Platform Trial will test multiple promising...
- Trial News & Webinars
All Healey & AMG Center News Sign Up: MGH ALS Link Register:...
- Collaboration
An essential element of the research efforts at the Healey &...
- Our Supporters
- Background on Adaptive Platform Trials
- The Healey Als Platform Trial
- Looking Ahead
APTs, which were pioneered in oncology, run indefinitely and investigate multiple therapies concurrently. They are typically run by a centralized coordination center with collaboration between academia, industry, government agencies, foundations and patients. A parent protocol is established at the outset of the trial, and therapies continually ent...
Inception—The primary aim of the Healey ALS Platform Trial is to compare the efficacy of novel/emerging therapies against a shared placebo group for participants with sporadic or familial ALS. Dr. Cudkowicz submitted the initial investigational new drug application to the FDA, so she serves as the study sponsor. Investigators communicated early wit...
The executive committee of the Healey Platform ALS Trial has the goal of engaging regulatory authorities outside the United States to discuss the implications of the APT approach for drug approvals in other countries. The other APT to watch in ALS is the Motor Neuron Disease–Systematic Multi-arm Adaptive Randomisation Trial (MND SMART), headquarter...
May 9, 2023 · The HEALEY ALS Platform Trial (NCT04297683), a first of its kind, phase 2/3, multicenter, randomized, placebo-controlled, multi-arm trial, is assessing several agents in development for amyotrophic lateral sclerosis (ALS).
The HEALEY ALS Platform Trial is a perpetual adaptive phase 2/3 multi-regimen trial that allows for shared trial infrastructure and use of shared placebo data. The initial four regimens have completed the randomized placebo-controlled treatment period.
Dec 20, 2023 · With the design in place, Healey put out a call to developers to submit drugs for its study. More than 30 applied, nearly all small biotechnology companies attracted by the center’s deep bench of experts and, crucially, its promise to cover a significant amount of the trial’s costs.
Professor Mick Healey's recent publications – Professor Healey has worked extensively linking discipline-based research and teaching and engaging students in research and inquiry. Good for getting an overview of how research-informed teaching has developed in the UK context and reviewing benefits for students, academics, departments and ...
People also ask
Who supports the Healey ALS platform trial?
What is Healey Center for ALS?
What does the Healey Center do?
Professor Healey's book is a thoughtful and penetrating discussion of issues in foreign language teaching at the university level that should be of interest and value to all concerned with these issues - not only to the professional language
